In a secondary efficacy analysis, no patient in either treatment arm had a complete response. The incidence of patient responses was 34% in the PHP patients and 2% in the controls. The combined rate of partial response or stable disease reached 86% in the PHP-treated patients and 28% in the control patients.
The trial was sponsored in part by Delcath, the company developing the PHP system. Dr. Notting said that he has received research support from, and has spoken on behalf of, Delcath.